These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 12091003)

  • 21. Pulse pressure and antihypertensive agents.
    Safar ME; O'Rourke MF
    Hypertension; 2005 Aug; 46(2):e6; author reply e6-7. PubMed ID: 16027242
    [No Abstract]   [Full Text] [Related]  

  • 22. [Results from the LIFE study: promising effects of new hypertensive agents].
    Nilsson P; Kahan T
    Lakartidningen; 2002 Apr; 99(16):1792-4. PubMed ID: 12043477
    [No Abstract]   [Full Text] [Related]  

  • 23. [LIFE study proves preventive action. With losartan to do even more against stroke].
    Baumgart P
    MMW Fortschr Med; 2003; 145 Suppl 1():7-8. PubMed ID: 12958796
    [No Abstract]   [Full Text] [Related]  

  • 24. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Devereux RB; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Slower heart rates for healthy hearts: time to redefine tachycardia?
    Gopinathannair R; Sullivan RM; Olshansky B
    Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):321-3. PubMed ID: 19808425
    [No Abstract]   [Full Text] [Related]  

  • 26. [Angiotensin 1-antagonists: primary therapeutic option in arterial hypertension, too].
    Traut
    Dtsch Med Wochenschr; 2003 Jan; 128(4):161; discussion 161-2. PubMed ID: 12589590
    [No Abstract]   [Full Text] [Related]  

  • 27. The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study.
    Fossum E; Gleim GW; Kjeldsen SE; Kizer JR; Julius S; Devereux RB; Brady WE; Hille DA; Lyle PA; Dahlöf B
    J Intern Med; 2007 Oct; 262(4):439-48. PubMed ID: 17875180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [What are the consequences of the LIFE Study for general practice].
    Zidek W
    MMW Fortschr Med; 2002 Sep; 144(38):48. PubMed ID: 12395704
    [No Abstract]   [Full Text] [Related]  

  • 29. Might losartan reduce sudden cardiac death in diabetic patients with hypertension?
    Aronow WS
    Lancet; 2003 Aug; 362(9384):591-2. PubMed ID: 12944056
    [No Abstract]   [Full Text] [Related]  

  • 30. Diuretics in the LIFE study.
    Kato J; Eto T
    Lancet; 2004 Jul 31-Aug 6; 364(9432):413; author reply 413-4. PubMed ID: 15288732
    [No Abstract]   [Full Text] [Related]  

  • 31. [German Hypertension League on the LIFE Study. New evaluation of AT1 receptor antagonists].
    Dominiak P; Zidek W
    MMW Fortschr Med; 2002 Sep; 144(38):47. PubMed ID: 12395703
    [No Abstract]   [Full Text] [Related]  

  • 32. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
    Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Isolated systolic hypertension. "AT1 blocker preferred over beta-blocker"].
    MMW Fortschr Med; 2002 Sep; 144(38):14. PubMed ID: 12395694
    [No Abstract]   [Full Text] [Related]  

  • 34. [Therapy of hypertension in patients with atrial fibrillation. Sartan is superior to beta-blocker].
    MMW Fortschr Med; 2003 May; 145(19):53. PubMed ID: 12813983
    [No Abstract]   [Full Text] [Related]  

  • 35. [LIFE-study: losartan reduces cardiovascular risk factors more than atenolol].
    Heinzl S
    Med Monatsschr Pharm; 2002 May; 25(5):149. PubMed ID: 12050919
    [No Abstract]   [Full Text] [Related]  

  • 36. [Plus point -- risk reduction].
    MMW Fortschr Med; 2006 Aug; 148(33-34):56-7. PubMed ID: 16981392
    [No Abstract]   [Full Text] [Related]  

  • 37. Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
    Bursztyn M
    Lancet; 2002 Jun; 359(9324):2201; author reply 2203-4. PubMed ID: 12091006
    [No Abstract]   [Full Text] [Related]  

  • 38. Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
    Montastruc JL; Pathak A; Lapeyre-Mestre M
    Lancet; 2002 Jun; 359(9324):2202; author reply 2203-4. PubMed ID: 12091009
    [No Abstract]   [Full Text] [Related]  

  • 39. Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
    Hjelmesaeth J; Carlsson PO
    Lancet; 2002 Jun; 359(9324):2201-2; author reply 2203-4. PubMed ID: 12091007
    [No Abstract]   [Full Text] [Related]  

  • 40. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
    Carr AA; Kowey PR; Devereux RB; Brenner BM; Dahlöf B; Ibsen H; Lindholm LH; Lyle PA; Snapinn SM; Zhang Z; Edelman JM; Shahinfar S
    Am J Cardiol; 2005 Dec; 96(11):1530-6. PubMed ID: 16310435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.